Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel.

ABSTRACT:

Background

Glioblastoma (GBM) is a primary malignancy of the central nervous system and is classified as a grade IV astrocytoma by the World Health Organization (WHO). Although GBM rarely metastasizes, its prognosis remains poor. Moreover, the standard treatment for GBM, temozolomide (TMZ), is associated with chemoresistance, which is a major factor behind GBM-related deaths. Investigating drugs with repurposing potential in the context of GBM is worthwhile to bypass lengthy bench-to-bedside research. The field of omics has garnered significant interest in scientific research because of its potential to delineate the intricate regulatory network underlying tumor development. In particular, proteomic and metabolomic analyses are powerful approaches for the investigation of metabolic

SUBMITTER: Ahmed M 

PROVIDER: S-EPMC10810643 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature